Daily Sepsis Research Analysis
Analyzed 31 papers and selected 3 impactful papers.
Summary
Three mechanistic sepsis studies advance therapeutic targeting and organ protection. A novel LRR-domain NLRP3 inhibitor overcomes MCC950 resistance with in vivo efficacy, while two studies reveal ferroptosis-centered pathways in sepsis-associated kidney and cardiac injury, identifying actionable transcriptional regulators (SMAD4→HO-1 and ERRα→METRNL).
Research Themes
- Inflammasome-targeted therapeutics that overcome MCC950 resistance
- Ferroptosis regulation in sepsis-associated organ injury (kidney and heart)
- Transcriptional control as a lever for cardioprotection in septic cardiomyopathy
Selected Articles
1. Pharmacological targeting of the NLRP3 LRR domain with isothiazolinones overcomes CRID3-resistant inflammation.
High-throughput screening identified LOC14, an isothiazolinone inhibitor that binds the NLRP3 LRR domain and suppresses both MCC950-sensitive and -resistant NLRP3 variants. LOC14 reduced inflammation in vivo across colitis, sepsis, and psoriasis models, and structure–activity data implicated the isothiazol-3(2H)-one carbonyl oxygen as essential for activity.
Impact: This work introduces a new mechanistic class of NLRP3 inhibitors that overcomes a key limitation of MCC950, with demonstrated efficacy in a sepsis model.
Clinical Implications: Although preclinical, LRR-domain–targeted NLRP3 inhibitors could broaden treatment options for NLRP3-driven conditions including sepsis; safety, PK, and human validation are needed.
Key Findings
- LOC14, an isothiazolinone-containing small molecule, selectively inhibits NLRP3 by binding to or near its LRR domain.
- LOC14 suppresses both MCC950 (CRID3)-responsive and -non-responsive hyperactive/gain-of-function NLRP3 variants.
- The carbonyl oxygen of the isothiazol-3(2H)-one moiety is critical for inhibitory activity.
- In vivo anti-inflammatory efficacy was demonstrated in mouse models of colitis, sepsis, and psoriasis.
Methodological Strengths
- High-throughput screening with structure–activity relationship elucidation.
- Mechanistic validation across mutant NLRP3 variants and multiple in vivo disease models including sepsis.
Limitations
- Lack of human data; pharmacokinetics/toxicology not comprehensively characterized.
- Isothiazolinones are reactive electrophiles, raising potential off-target/toxicity concerns.
Future Directions: Optimize potency and safety, perform PK/PD and toxicity studies, evaluate efficacy in polymicrobial sepsis (e.g., CLP) and define translational biomarkers for clinical development.
The NLRP3 inflammasome is a key driver in inflammatory, infectious, metabolic, and neurodegenerative diseases. Although the NLRP3 inhibitor CRID3 (also known as MCC950) exhibits potent activity, it cannot inhibit several hyperactive NLRP3 mutations associated with autoinflammatory syndromes and has not progressed clinically, underscoring the need for the development of new NLRP3 inhibitors. Through a high-throughput screening, we identified LOC14, an isothiazolinone-containing small molecule, as a selective NLRP3 inhibitor. Distinct from CRID3, which targets the NACHT domain, LOC14 binds to or near the LRR domain of NLRP3 and inhibits both CRID3-responsive and CRID3-non-responsive hyperactive or gain-of-function NLRP3 variants. Furthermore, we identified that the carbonyl oxygen of the isothiazol-3(2H)-one moiety is critical for inhibitory activity. In vivo, LOC14 exerted anti-inflammatory activity in mouse models of colitis, sepsis, and psoriasis, demonstrating broad physiological and therapeutic relevance. Our findings highlight isothiazolinone-containing compounds as selective NLRP3 inhibitors and provide a promising foundation for developing therapies targeting NLRP3-driven inflammatory diseases.
2. ERRα transcriptionally activates METRNL, ameliorating cardiomyocyte apoptosis and inflammatory injury in septic cardiomyopathy through the NF-κB/NLRP3 pathway.
In a CLP mouse model and LPS-stimulated cardiomyocytes, ERRα expression was reduced during sepsis, while cardiomyocyte-specific ERRα overexpression improved survival, cardiac function, and reduced inflammation/apoptosis. Mechanistically, ERRα transcriptionally activated METRNL and inhibited NF-κB/NLRP3 signaling; METRNL knockdown abrogated ERRα’s protective effects.
Impact: Identifies a druggable transcriptional axis (ERRα→METRNL) that improves survival and cardiac injury in septic cardiomyopathy, providing a mechanistic basis for targeted cardioprotection.
Clinical Implications: Supports development of ERRα agonists or METRNL-based strategies to prevent/treat septic cardiomyopathy; requires translational safety/pharmacology and validation in large-animal models.
Key Findings
- ERRα is downregulated in septic hearts; cardiomyocyte-specific overexpression via AAV-9 improves survival and cardiac function after CLP.
- ERRα overexpression suppresses inflammatory cytokines and apoptosis in LPS-stimulated HL-1 cardiomyocytes.
- METRNL is a direct transcriptional target of ERRα; METRNL knockdown blocks the anti-inflammatory and anti-apoptotic effects of ERRα.
- ERRα inhibits NF-κB/NLRP3 inflammasome activation in septic myocardium and cardiomyocytes.
Methodological Strengths
- Integrated in vivo CLP model with cardiomyocyte-specific gene modulation and in vitro validation.
- Robust target validation using dual-luciferase reporter assays, ChIP-qPCR, and oligonucleotide pull-down.
Limitations
- Preclinical study; translatability of AAV-9 gene delivery and long-term safety are uncertain.
- Single primary sepsis model (CLP) and lack of sex-specific analyses limit generalizability.
Future Directions: Evaluate small-molecule ERRα agonists or METRNL delivery, assess dosing windows in polymicrobial sepsis, and validate efficacy/safety in large-animal models prior to early-phase trials.
Septic cardiomyopathy (SCM) is a prevalent complication among septic patients, accompanied by high mortality. Estrogen-related receptor alpha (ERRα), a transcription factor, is implicated in various cardiovascular diseases. Nonetheless, its role in SCM remains unclear. Here, the cecum ligation and puncture (CLP) procedure was used to construct a mouse sepsis model. We found that the ERRα expression was downregulated in septic hearts. Adeno-associated virus-9 (AAV-9)-mediated cardiomyocyte-specific ERRα overexpression improved the survival rate of septic mice. Additionally, ERRα overexpression ameliorated CLP-induced cardiac dysfunction and myocardial pathological damage. In vitro, HL-1 mouse cardiomyocytes were transduced with an ERRα overexpression adenovirus before LPS stimulation. The results demonstrated that ERRα overexpression mitigated LPS-induced inflammatory cytokines (IL-6, IL-1β, TNF-α, IL-18) and apoptosis (Bax, cleaved caspase-3/9) in HL-1 cells. Mechanistically, ERRα inhibited the NF-κB/NLRP3 inflammasome activation in septic hearts and LPS-stimulated HL-1 cells. Furthermore, we overlapped the differentially expressed genes of septic hearts (GSE125042) and ERRα KO hearts (GSE7196) to identify the downstream target genes. Meteorin like, glial cell differentiation regulator (METRNL) was identified as the target gene of ERRα. Notably, ERRα bound to the METRNL promoter and upregulated its activity, which was confirmed via dual-luciferase reporter assay, ChIP-qPCR, and oligonucleotide pull-down assay. Knockdown of METRNL prevented the effects of ERRα overexpression on the apoptosis and inflammatory response of cardiomyocytes induced by LPS. Our findings underscore the role of ERRα in mitigating myocardial injury in SCM, indicating its potential as a new therapeutic approach.
3. SMAD4 Inhibits HO-1-Driven Ferroptosis Through Transcriptional Repression in Sepsis-Associated Acute Kidney Injury.
In CLP-induced SA-AKI, ferroptosis is strongly activated with robust HO-1 upregulation. SMAD4 directly binds the HO-1 promoter to repress transcription; SMAD4 overexpression reduces ferroptosis and improves renal function across in vivo and in vitro models.
Impact: Reveals a previously unrecognized SMAD4–HO-1 regulatory axis governing ferroptosis in SA-AKI, nominating tractable nodes for therapeutic intervention.
Clinical Implications: Supports targeting ferroptosis and SMAD4–HO-1 signaling to protect renal function in sepsis; translational studies and druggable modulators are needed.
Key Findings
- Ferroptosis is markedly activated in SA-AKI with increased ROS, lipid peroxidation, ferrous iron, and HO-1 expression.
- SMAD4 binds the HO-1 promoter and represses its transcription, validated by ChIP-qPCR and dual-luciferase assays.
- SMAD4 overexpression reduces HO-1, alleviates ferroptosis, and improves renal function in vivo and in vitro.
Methodological Strengths
- Combination of spatial proteomics with functional assays across in vivo and in vitro systems.
- Mechanistic validation of transcriptional control using DNA pull-down, ChIP-qPCR, and reporter assays.
Limitations
- Preclinical scope without human tissue validation or clinical correlation.
- Therapeutic modulation of SMAD4/HO-1 was limited to overexpression; small-molecule or genetic inhibition studies are needed.
Future Directions: Develop selective modulators of SMAD4–HO-1 signaling, test ferroptosis-targeting combinations in polymicrobial sepsis, and evaluate biomarkers to stratify SA-AKI patients.
BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) is a frequent and severe complication in critically ill patients, yet effective targeted therapies are lacking. Ferroptosis has been implicated in various forms of organ injury, but its role in SA-AKI and underlying regulatory mechanisms remain unclear. METHODS: A SA-AKI mouse model was established using cecal ligation and puncture (CLP). Renal histopathology, kidney function assays, and spatial proteomics were employed to assess ferroptosis activation. In vivo and in vitro models were subjected to lipopolysaccharide (LPS) stimulation to evaluate ferroptosis-related markers, including reactive oxygen species (ROS), lipid peroxidation, ferrous iron levels, and mitochondrial membrane potential. DNA pull-down coupled with mass spectrometry identified potential upstream regulators of HO-1. Chromatin immunoprecipitation-quantitative polymerase chain reaction (ChIP-qPCR) and dual-luciferase reporter assays were used to validate transcriptional regulation by SMAD4. Functional studies assessed the impact of SMAD4 on HO-1 expression, ferroptosis, and renal function. RESULTS: Ferroptosis was markedly activated during SA-AKI progression. LPS stimulation induced significant ROS accumulation, lipid peroxidation, elevated ferrous iron levels, mitochondrial membrane potential disruption, and robust upregulation of heme oxygenase-1 (HO-1). SMAD4 was identified as a transcriptional repressor of HO-1. ChIP-qPCR and dual-luciferase assays confirmed SMAD4 binding to the HO-1 promoter and suppression of its transcription. SMAD4 overexpression reduced HO-1 expression, alleviated ferroptosis, and improved renal function in both in vivo and in vitro models. CONCLUSIONS: SMAD4 mitigates ferroptosis by transcriptionally repressing HO-1, exerting a protective effect in SA-AKI. This study identifies a novel SMAD4-HO-1 regulatory axis and suggests a potential therapeutic target for sepsis-induced kidney injury.